Biosecurity

Can Antibody Engineering Finally Defeat Glioblastoma?
Biotech & Bioprocessing Can Antibody Engineering Finally Defeat Glioblastoma?

The relentless progression of oncology over the past several decades has fundamentally altered the prognosis for many once-terminal cancers, yet glioblastoma remains a stubborn outlier in this narrative of medical triumph. While the integration of immune checkpoint inhibitors and targeted

Lilly Trial Validates Dual Therapy for Psoriasis and Obesity
Biotech & Bioprocessing Lilly Trial Validates Dual Therapy for Psoriasis and Obesity

The long-standing clinical practice of treating chronic inflammatory diseases and metabolic disorders as entirely separate medical concerns is currently undergoing a radical transformation as new research underscores their deep biological interconnectedness. Traditionally, the medical community has

EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment
Biotech & Bioprocessing EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment

Managing severe, persistent respiratory conditions often feels like a relentless battle, with frequent treatments and the constant threat of debilitating flare-ups dictating the rhythm of daily life. For millions, conditions like severe asthma and chronic rhinosinusitis with nasal polyps represent

Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial
Biotech & Bioprocessing Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial

A groundbreaking Phase III clinical trial has revealed that the therapy Gazyva (obinutuzumab) demonstrates superior efficacy over the current standard-of-care treatment, tacrolimus, for adults grappling with primary membranous nephropathy. The MAJESTY trial’s success represents a significant

VectorY Launches Landmark Trial for Novel ALS Gene Therapy
Biotech & Bioprocessing VectorY Launches Landmark Trial for Novel ALS Gene Therapy

A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical

Why Did South Dakota Choose a Pause Over a Ban?
Biotech & Bioprocessing Why Did South Dakota Choose a Pause Over a Ban?

The emergence of cell-cultured protein has sparked intense debate at the intersection of agricultural tradition and technological innovation, nowhere more so than in states with deep roots in the livestock industry. In South Dakota, a legislative effort to completely prohibit the sale of lab-grown

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later